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Pneumococcal conjugate vaccines (PCVs) have been successful in preventing invasive pneumococcal disease but
effectiveness has been challenged by replacement of vaccine serotypes with non-vaccine serotypes. Vaccines targeting
common pneumococcal protein(s) found in most/all pneumococci may overcome this limitation. This phase II study
assessed safety and immunogenicity of a new protein-based pneumococcal vaccine containing polysaccharide
conjugates of 10 pneumococcal serotypes combined with pneumolysin toxoid(dPly) and pneumococcal histidine triad
protein D(PhtD) (PHiD-CV/dPly/PhtD-30) in African children. 120 Gambian children (2–4 years, not previously vaccinated
against Streptococcus pneumoniae) randomized (1:1) received a single dose of PHiD-CV/dPly/PhtD-30 or PCV13. Adverse
events occurring over 4 d post-vaccination were reported, and blood samples obtained pre- and 1-month post-
vaccination. Serious adverse events were reported for 6 months post-vaccination. Solicited local and systemic adverse
events were reported at similar frequency in each group. One child (PHiD-CV/dPly/PhtD-30 group) reported a grade 3
local reaction to vaccination. Haematological and biochemical parameters seemed similar pre- and 1-month post-
vaccination in each group. High pre-vaccination Ply and PhtD antibody concentrations were observed in each group,
but only increased in PHiD-CV/dPly/PhtD-30 vaccinees one month post-vaccination. One month post-vaccination, for
each vaccine serotype 96.2% of PHiD-CV/dPly/PhtD-30 vaccinees had serotype-speciﬁc polysaccharide antibody
concentrations 0.20mg/mL except serotypes 6B (80.8%) and 23F (65.4%), and 94.1% had OPA titres of 8 except
serotypes 1 (51.9%), 5 (38.5%) and 6B (78.0%), within ranges seen in PCV13-vaccinated children. A single dose of PHiD-
CV/dPly/PhtD-30 vaccine, administered to Gambian children aged 2–4 y not previously vaccinated with a
pneumococcal vaccine, was well-tolerated and immunogenic.
Introduction
Pneumococcal pneumonia and invasive pneumococcal disease
(IPD), caused by Streptococcus pneumoniae, are responsible for
about 500,000 deaths each year among children <5 years, with
the majority of these deaths occurring in developing countries.1
S. pneumoniae has over 90 serotypes and normally inhabits the
nasopharynx from where it can spread to cause otitis media,
sinusitis or pneumonia, or invade the circulation to cause bacter-
aemia, septicaemia or meningitis.
Pneumococcal conjugate vaccines (PCVs) containing polysac-
charides (PS) coupled to a non-pneumococcal protein have
reduced the burden of pneumococcal diseases due to vaccine
serotypes worldwide. 2-5 In the US, PCV7 covered >80% of the
serotypes responsible for IPD prior to vaccination and dramati-
cally decreased vaccine type IPD. Coverage in Africa was less,
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about 60%.6,7 The restricted coverage provided by PCV7 led to
the development of PCVs with additional serotypes, in particular
serotypes 1 and 5, common in Africa, as recognized by WHO in
the target profile for global PCVs targeted for the advance market
commitment. However, global control of pneumococcal disease
may be difficult to achieve due to serotype replacement, technical
limitations in the number of PS that can be included and the
high cost of PCVs.6-8 A potential solution to overcome the
PCVs’ limitations is the development of vaccines containing
pneumococcal protein(s) well conserved across all pneumococci.
An investigational vaccine containing 2 proteins - pneumo-
coccal histidine triad protein D (PhtD) and pneumolysin tox-
oid (dPly standing for “detoxified pneumolysin”) is being
developed. PhtD, one of the proteins expressed on the surface
of the pneumococcus, is thought to be involved in invasion9
and in inhibition of complement deposition through binding
to factor H.10,11 PhtD is involved in zinc homeostasis and is
crucial for host colonization and invasion.12 Pneumolysin (Ply)
is an exotoxin released during bacterial autolysis.13 Ply is a
multifunctional haemolytic cytolysin that plays a role in the
early pathogenesis of IPD by facilitating intrapulmonary bacte-
rial growth and invasion of the blood.13 Antibodies to these
proteins could promote neutralization of important toxic or
enzymatic functions of pneumococci and inhibit adherence of
the bacteria to epithelial cells.14,15 In animal studies, immuni-
zation with dPly and/or PhtD protected against nasopharyngeal
colonization, septicaemia, lethal challenge and pneumonia due
to various serotypes.10,14-17
dPly and PhtD, administered alone or in combination with a
10-valent PCV (PCV10), were well tolerated and immunogenic
in healthy young adults,18,19 chil-
dren and infants in Europe.20-22
The safety and immunogenicity
of this pneumococcal protein-
based vaccine could, however, be
different in African settings where
there is a high prevalence of naso-
pharyngeal carriage of S. pneumo-
niae and a high incidence of
pneumococcal disease. Therefore,
a cautious approach was adopted
to evaluate the safety profile of
this vaccine in African children.
We describe here the results of a
pilot safety assessment of an
investigational vaccine containing
30 mg of each dPly and PhtD
combined with a 10-valent pneu-
mococcal conjugate vaccine
(PHiD-CV/dPly/PhtD-30) in
Gambian children aged 2–4 y
prior to the conduct of a larger
trial in infants. (www.clinical
Trials.gov NCT01262872).
However, this study was not
powered to detect differences
between study groups in immune
responses to the vaccines.
Results
Study participants
One hundred and twenty chil-
dren aged 2–4 y were enrolled
and randomized, all of whom
received one dose of either
PHiD-CV/dPly/PhtD-30 or
PCV13. All completed the last
study visit. Seventeen children (8
receiving PHiD-CV/dPly/PhtD-
Figure 1. Trial Consort. N: number of enrolled children; ATP: according-to-protocol; PHiD-CV/dPly/PhtD-30:
Children receiving a single dose of an investigational vaccine containing polysaccharide conjugates of PHiD-
CV combined with 30 mg each of dPly and PhtD pneumococcal proteins; PCV13: Children receiving a single
dose of Prevnar13.
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30; 9 receiving PCV13) were excluded from the ATP safety and
immunogenicity cohort as they received a concomitant vaccine
(OPV) given during a mass campaign against polio after receiving
the study vaccine (Fig. 1). The demographic characteristics of the
2 groups were comparable. The mean (SD) age of PHiD-CV/
dPly/PhtD-30 children was 2.8 (0.40) years and that of the
PCV13-vaccinated children was 2.9 (0.36) years. There were 41
(68.3%) girls in the PHiD-CV/dPly/PhtD-30 group and 26
(43.3 %) in the PCV13 group. All the children were of African
ancestry.
Safety and reactogenicity
Grade 3 vaccine-related swelling was reported at the injection
site in one child receiving PHiD-CV/dPly/PhtD-30. There were
no episodes of general swelling of the vaccinated limb in either
study groups during the 4-day post-vaccination period. The over-
all incidence of solicited general AEs was in similar ranges in both
groups. No grade 3 general solicited AEs were reported. Fever,
the most frequently reported solicited general AE, was reported
in 4 (6.7%) children receiving PHiD-CV/dPly/PhtD-30 and in
2 (3.3%) children receiving PCV13; for one subject in each
group, fever was considered to be causally related to vaccination
by the investigator. Loss of appetite was reported for one child
receiving PHiD-CV/dPly/PhtD-30. No other solicited local or
general AEs in either group were reported. At least one unsolic-
ited AE was reported for 21.7%
(95% CI 12.1%–34.2%) of chil-
dren receiving PHiD-CV/dPly/
PhtD-30 and for 11.7% (95% CI
4.8%–22.6%) receiving PCV13.
The most frequently reported
unsolicited AE in the PHiD-CV/
dPly/PhtD-30 group was respira-
tory tract infection (8.3%) while
tinea capitis was the most fre-
quently reported AE in the PCV13
group (3.3%). Prophylactic use of
an antipyretic was not reported in
either group and for only one child
in the PCV13 group antipyretic
use was reported during the 4-days
post-vaccination period. No SAEs
were reported throughout the
extended safety period of 6
months.
The pre-vaccination ALT level
of one child receiving PHiD-CV/
dPly/PhtD-30 was of a grade 3
reaction, but this fell to a normal
level one month post-vaccination.
The result of biochemical parame-
ters were not known before vacci-
nation. There were no other
clinically significant abnormalities
in the haematological or biochemi-
cal measurements.
Immune response to Ply and PhtD
Pre-vaccination, Ply and PhtD GMCs were in similar ranges
in each group. All children receiving PHiD-CV/dPly/PhtD-30
and 98% of children receiving PCV13 had Ply antibody titres
599 LU/ml. Similarly all the children in each group had PhtD
antibody titres 399 LU/ml. One month after vaccination, Ply
and PhtD GMCs tended to be higher in the PHiD-CV/dPly/
PhtD-30 group compared to pre-vaccination levels. No increase
was observed in the PCV13 group (Fig. 2).
Immune response to pneumococcal serotype-specific PS
conjugates
For each vaccine serotype there were increases in PS
GMCs and GMTs from pre- to post-vaccination in each
group (Tables 1 and 2). For each of the 10 common vaccine
serotypes, the percentage of children with an antibody con-
centration of 0.2 mg/ml pre-vaccination ranged from 9.6% to
63.5% in the PHiD-CV/dPly/PhtD-30 group and from 9.8% to
62.7% in the PCV13 group reflecting an existing baseline sero-
positivity rate; one month post-vaccination, 96.2% of the
PHiD-CV/dPly/PhtD-30-vaccinated children had serotype-spe-
cific PS GMCs 0.2 mg/ml except for antibodies to serotypes 6B
(80.8%) and 23F (65.4%), figures seem to be comparable to those
found in PCV13-vaccinated children (96.1% had PS GMCs of
0.2 mg/ml) except for antibodies to serotypes 6B (90.2%) and
Figure 2. Ply and PhtD antibody geometric mean concentrations pre- and 1-month post vaccination. N:
number of enrolled children; Pre: before vaccination; Post: one month after vaccination; GMC: geometric
mean antibody concentrations; PHiD-CV/dPly/PhtD-30: Children receiving a single dose of an investigational
vaccine containing polysaccharide conjugates of PHiD-CV combined with 30 mg each of dPly and PhtD
pneumococcal proteins; PCV13: Children receiving a single dose of Prevenar 13. (The error bars represent
standard deviation.
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23F (90.2%). Cross-reactivity is said to occur when a vaccine con-
taining a serotype (e.g. 6B) but no other serotypes in the same
serogroup (serogroup 6) is administered to an individual and indu-
ces antibody production against other serotype(s) (e.g. 6A) in the
same serogroup. Pre-vaccination, 30.8% and 17.6% of PHiD-
CV/dPly/PhtD-30-vaccinated and PCV13-vaccinated children
respectively had antibody concentrations of 0.2 mg/ml against
serotype 6A while 61.5% and 49.0% of PHiD-CV/dPly/PhtD-
30-vaccinated and PCV13-vaccinated children respectively had
GMCs of 0.2 mg/ml against serotype 19A. Post-vaccination, for
cross-reactive serotypes 6A and 19A, the percentages of children
with PS GMCs 0.2 mg/ml in the PHiD-CV/dPly/PhtD-30-vac-
cinated group were 42.3% and 92.3% respectively compared to
values of 90.2% and 100% respectively in the PCV13 vaccinated
group. For each of the 10 common vaccine serotypes, over 94.1%
of PHiD-CV/dPly/PhtD-30-vaccinated children had GMTs of
8 except for serotypes 1 (51.9%), 5 (38.5%) and 6B (78.0%).
For each of the 10 common vaccine serotypes, over 96.1% of the
PCV13-vaccinated children had GMTs of 8 except for serotypes
1 (90.0%) and 5 (89.8%).
For cross-reactive serotypes 6A and 19A, the percentages of
children who had GMTs 8 were 78.7% and 98% respectively
in the PHiD-CV/dPly/PhtD-30-vaccinated (cross-reactive anti-
bodies) compared with 100% and 100% respectively in the
PCV13-vaccinated group (Table 2).
Immune response to Haemophilus influenzae protein D
The percentage of children who had pre-vaccination antibody
titres to NTHi protein D above the cut-off value was 15.4% in
the PHiD-CV/dPly/PhtD-30 group vs. 13.7% in the PCV13
group. One month post-vaccination, the percentage was 61.5%
for the PHiD-CV/dPly/PhtD-30-vaccinated children while no
increase in GMC or seropositivity rate was observed in the
PCV13 group (13.7% in PCV13) (Table 3).
Discussion
Pneumococcal proteins are promising antigens for vaccine
development as they induce functional antibodies 23 and protect
animals against pneumococcal infection.14,15 We have evaluated
the reactogenicity, safety and immunogenicity of PHiD-CV/
dPly/PhtD-30 when given as a single dose to Gambian children
aged 2–4 y. This was the first time that a protein-based pneumo-
coccal vaccine has been administered to African children.
Vaccine tolerability seemed to be comparable between the
PHiD-CV/dPly/PhtD-30 and PCV13 groups. There were no
safety concerns raised throughout the study period; only one
grade 3 local reaction (swelling) was reported in the PHiD-CV/
dPly/PhtD-30 group. There were no clinically significant haema-
tological or biochemical toxicities observed post-vaccination.
One child receiving PHiD-CV/dPly/PhtD-30 had an elevated
ALT level pre-vaccination but this was normal one month post-
vaccination. The results of the biochemistry tests were not known
at the time of vaccination. The elevated ALT pre-vaccination
could have been due to a subclinical liver infection such as hepati-
tis A. No SAEs were reported throughout the study period
including the safety follow-up period of 6 months.
All children had measurable Ply and PhtD antibody titres pre-
vaccination. The background antibody titres may be due to the
high nasopharyngeal carriage of S. pneumoniae reported in this
population.24-26 Regardless of this high background, both dPly
and PhtD were still highly immunogenic in African children as
in European adults19 and children.20 The post-vaccination
GMCs against pneumococcal proteins that are associated with
protection against pneumococcal diseases in humans have not
been determined so far. The licensure pathway for pneumococcal
protein-based vaccines has not been defined yet. Therefore, in
addition to immunogenicity results, further assessment of the
efficacy of this pneumococcal protein vaccine against nasopha-
ryngeal carriage is currently ongoing.
In our study population, despite the existing pre-vaccination
antibody levels, there was a substantial increase from pre-vaccina-
tion to post-vaccination levels for anti-Ply and anti-PhtD which
is within a 2-fold increase. These existing pre-vaccination levels
of anti-Ply and anti-PhtD may be because the participants were
already exposed to S. pneumoniae. The immune response in
infants, the desired target population who have not had such
exposure may be different; following 2 or 3 primary doses the
responses may be higher and long lasting compared to one dose.
Furthermore, the functionality of these antibodies was not quan-
tified. However, the proteins have been shown to protect against
Table 3. Immune responses to dPly, PhtD and PD pre- and one month post-vaccination (ATP immunogenicity cohort).
Antigen PHiD-CV/dPly/PhtD-30 PCV13
dPly n %  599 LU/mL (95% CI) GMC, LU/mL (95% CI) n %  599 LU/mL (95% CI) GMC, LU/mL (95% CI)
Pre 52 100.0 (93.2–100.0) 10833.1(8582.8–13673.4) 51 100.0 (93.0–100.0) 8939.0(7111.5–11236.2)
Post 52 100.0(93.2–100.0) 22794.9(17570.1–29573.3) 50 98.0(89.6–100.0) 8510.3 (6668.5–10860.8)
PhtD n %  391 LU/mL(95% CI) GMC, LU/mL(95% CI) n %  391 LU/mL(95% CI) GMC, LU/mL (95% CI)
Pre 52 100.0 (93.2–100.0) 19757.9 (16524.8–23623.6) 51 100.0 (93.0–100.0) 17796.9 (14753.0–21468.8)
Post 52 100.0 (93.2–100.0) 31326.3 (26293.9–37321.8) 51 100.0 (93.0–100.0) 16810.0 (13516.3–20906.4)
PD n %  112 LU/mL(95% CI) GMC, LU/mL(95% CI) n %  112 LU/mL(95% CI) GMC, LU/mL (95% CI)
Pre 52 15.4(6.9–28.1) 65.6(58.8–73.3) 51 13.7(5.7–26.3) 63.5(57.9–69.6)
Post 52 61.5(47.0–74.7) 137.5(108.4–174.4) 51 13.7(5.7–26.3) 65.1(58.2–72.8)
n D number of subjects with available results, GMC, geometric mean concentration, CID conﬁdence interval
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pneumococcal infection in preclinical studies. In the infant
cohort of this study we assess the immune response and effect of
nasopharyngeal carriage of S. pneumoniae.
Increases in serotype-specific PS GMCs and GMTs were
observed in children receiving PHiD-CV/dPly/PhtD-30. It is
difficult to compare the immunogenicity of the investigational
vaccine with PHiD-CV as it was not used in this study. Also
there is insufficient data from studies of PHiD-CV with similar
settings, vaccine schedules and age group. However, the percen-
tages of children who attained the cut-off threshold of 0.2 mg/
mL in our study seemed to be similar to those seen in a study
where African infants were given PHiD-CV as a 3-primary dose
schedule using the 6–10–14 week schedule,27 for all the common
vaccine serotypes except 23F. The immune response to serotype
6B in the current study seemed to be lower compared to other
serotypes as seen in most PCV studies.28-31 Despite generally low
GMCs to serotypes 6B and 23F, the efficacy of PHiD-CV
against IPD, acute otitis media and pneumonia caused by these
serotypes has been demonstrated following infant vaccination.
29,32,33 Also, no enhancement of the immune responses measured
by OPA GMTs was observed in PHiD-CV/dPly/PhtD-30
vaccinees for serotype 3, suggesting that no detectable OPA
response was induced by the pneumococcal proteins against this
serotype. It should be noted that the immune response to pneu-
mococcal proteins may be acting on the bacteria through other
mechanisms of action than opsonic antibodies (e.g. anti-adhe-
sion, neutralizing of toxin activity).To the best of our knowledge,
the protective effect of PCVs following 1-dose catch-up vaccina-
tion in 2–4-years-old has not been assessed. The high proportion
of children with high GMCs prior to vaccination may be due to
high nasopharyngeal carriage and environmental exposure to
PCV7 serotypes24 which has been associated with a reduced
immune response to PCVs in early infancy.34
In our study, the seropositivity rate of antibodies to protein D
one month post-vaccination increased to 61.5% for the PHiD-
CV/dPly/PhtD-30-vaccinated children. This response is lower
compared to the values obtained in European toddlers.20 This
may be explained by the fact that these European toddlers
received 2 doses of the vaccine while children in our study
received only one dose. In another study, European children 2–5
y of age also received a single dose catch-up vaccination with
PHiD-CV. The seropositivity rate for antibodies to protein D
one month post-vaccination was 76.3%,35 which is in similar
range to the seropositivity rate found in our study.
The human microbiome is known to vary depending on the
diet/nutrition, geographic location and living conditions of the
population and affects immune responses to vaccines.36
The microbiome of Gambian children may be considered a
confounder to their responses to this investigational vaccine.
Therefore, generalization of the results should be done with
caution.
One limitation of this study is that it was not designed to
assess the impact of pneumococcal proteins on the PS-conjugate
vaccineas the controls in this study received PCV13. To do this
PHiD-CV should have been used as the comparator vaccine but
PCV13 was chosen for this study primarily addressing safety in
African children aged 2 to 4 y as PCV13 was about to be intro-
duced into the Gambian National Immunization Program.
However, a study evaluating the safety and immunogenicity of
this investigational product in European toddlers using PHiD-
CV as a comparator vaccine showed that the pneumococcal pro-
teins do not negatively impact antibody responses to vaccine sero-
types. 20 Another limitation includes the small sample size in this
study. However, the primary objective was to assess the safety of
the vaccine; immunogenicity analyses were mainly descriptive. A
larger sample size will be required to make conclusions on the
immune responses induced by these proteins and their potential
impact on pneumococcal carriage and disease. In this study we
used a threshold value of 0.2mg/ml, corresponding to WHO
working group’s 0.35mg/ml antibody concentration of IgG anti-
capsular PS, in order to characterize the vaccine response. This
threshold applied for immune responses measured one month
after completion of a primary series in infancy has been recom-
mended by WHO as non-inferiority threshold (0.35) for licen-
sure on new PCV against IPD. The clinical relevance of this
threshold after one dose in an older age group like in this study is
unknown. Lastly, there was an imbalance in the proportion of
girls in the PHiD-CV/dPly/PhtD-30 group compared to the
control group. The reason for this imbalance is that the randomi-
zation system does not account for gender when assigning
groups. Thus, the results are by chance and differences were not
expected because of this.
Conclusion
This study has shown that PHiD-CV/dPly/PhtD-30 was well
tolerated and immunogenic when administered as a single dose
to 2–4-year-old Gambian children who had not been previously
vaccinated against S. pneumoniae. The investigators have pro-
ceeded to a larger dose-and schedule-finding trial in Gambian
infants, assessing impact on nasopharyngeal carriage.
Methods
Study design
This phase II, randomized, observer-blind, controlled study
was conducted in the Fajikunda district of the Western Region of
The Gambia between February 2011 and September 2011.
Recruitment and randomization
Mothers who brought their infants for routine vaccination at
the Fajikunda Health Centre were asked if they had children
aged 2–4 y. According to routine Expanded Programme on
Immunization (EPI) vaccines in The Gambia, 2–4 year-old chil-
dren were expected to have completed their immunization com-
prising one dose each of Bacille-Calmette-Guerin, oral polio
vaccine (OPV) and hepatitis B vaccines given at birth, 3 doses
each of OPV and pentavalent vaccine containing diphtheria, per-
tussis, tetanus, hepatitis B and Haemophilus influenzae type b
antigens administered at 2, 3 and 4 months of age and measles
www.tandfonline.com 399Human Vaccines & Immunotherapeutics
and yellow fever vaccines given at 9 months of age. PCV had not
been introduced in The Gambia when these children were
infants. Children were eligible for inclusion if they were healthy,
had completed the primary series of EPI vaccines and had not
received any vaccination against S. pneumoniae. Exclusion criteria
included having received or planning to use other investigational
products during the study period, having received immunoglobu-
lins or other blood products, chronic use of immunosuppressive
therapy, having a confirmed or suspected immunodeficient state,
having an allergic disease likely to be worsened by any compo-
nent of the vaccines or being severely malnourished (defined as
weight for age Z-score less than -3). A computer-generated,
block-randomization program was used to assign randomly eligi-
ble participants in a 1:1 ratio to receive either a single dose of
PHiD-CV/dPly/PhtD-30 or PCV13 (Prevenar13TM; Pfizer,
USA). Children were assigned sequentially to the next available
study participant number. During the study, the parents of the
vaccinees and study staff responsible for endpoint evaluations
were blinded to which vaccine had been administered to an indi-
vidual child.
Vaccines
PHiD-CV/dPly/PhtD-30 contained 30 mg of each, dPly and
PhtD combined with the 10 polysaccharide conjugates of the
pneumococcal H. influenzae protein D conjugate vaccine
(PHiD-CV; SynflorixTM, GSK Vaccines), consisting of 1 mg of
PS for serotypes 1, 5, 6B, 7F, 9V, 14 and 23F and 3 mg for sero-
type 4 conjugated to protein D, 3 mg of PS for serotype 18C and
19F conjugated to tetanus toxoid and diphtheria toxoid, respec-
tively. The proteins (dPly and PhtD) were adsorbed on Alumi-
num Phosphate (500 mg Aluminum content per dose of
0.5 mL). An investigational vaccine containing 30 mg each of
dPly and PhtD was chosen as it has been shown to elicit higher
immune responses and no safety concerns in European young
adults 18 compared to the lower dose (10 mg). Safety of the
higher dose was to be confirmed in African children before initi-
ating Cohort 2 study in infants. The safety and reactogenicity
results of the 2-dose primary vaccination part of the study in
European toddlers20 were available before the initiation of the
Cohort 1 of this study (February 2011) and did not raise any
safety concerns in those vaccinated with PHiD-CV/dPly/PhtD-
30. Antigens were adsorbed onto aluminum phosphate adjuvant.
The comparator vaccine, PCV13, contains serotypes 1, 6A and
19A in addition to PHiD-CV serotypes, all individually conju-
gated to CRM197. Both vaccines were provided as a suspension
in pre-filled syringes. Vaccines were administered intramuscularly
into the deltoid region of the non-dominant arm.
Assessment of safety and reactogenicity
Each child was observed in the clinic for 30 minutes post-vac-
cination and vital signs were recorded. For 3 d post-vaccination
trained field staff visited each child at home daily and recorded
local (pain, redness, swelling) and general (fever, drowsiness, irri-
tability or loss of appetite) adverse events (AEs). The intensity of
all solicited AEs was graded on a scale of 1–3. Pain at the injec-
tion site was considered grade 3 if the child cried when the limb
was moved or if the limb was spontaneously painful. Redness
and swelling at the injection site were considered grade 3 if the
diameter was >30 mm. The presence of diffuse swelling or a
noticeable increase of limb circumference following vaccination
was also recorded. Irritability or drowsiness was considered grade
3 if a participant cried and would not be comforted or was
drowsy to an extent that prevented normal activity, respectively.
All solicited local symptoms were considered causally related to
vaccination. Mothers/guardians were encouraged to bring their
child to the health center at any time if the child was unwell.
Unsolicited AEs were recorded for 31 d post-vaccination. Serious
adverse events (SAEs), defined as any untoward medical occur-
rence that resulted in death, was life-threatening, required hospi-
talization or prolongation of existing hospitalization or resulted
in disability/incapacity, were reported throughout the study
period. SAEs were reported over a period of 6 months post-vacci-
nation. Assessment of the causal relationship of solicited general
AEs, unsolicited AEs and SAEs to vaccination was based on the
clinical judgment of the investigators. Blood samples were
obtained pre- and one month post-vaccination for serological,
haematological (haemoglobin, white cell and platelet counts) and
biochemical (serum alanine transaminase (ALT) and creatinine)
measurements. Haematological and biochemical measurements
were performed at the clinical laboratory of the Medical Research
Council Unit, The Gambia as described previously.37 Safety
oversight for the study was provided by an Independent Data
Monitoring Committee.
Immunological assays
Sera were stored at ¡20C until analyzed. Serotype-specific
antibodies against the vaccine serotypes were measured using GSK
Biologicals’ 22F-inhibition ELISA, as described previously.38-40
GMCs of 0.2 mg/ml corresponded to the threshold value of
0.35 mg/ml in the WHO reference ELISA for comparison of new
PCVs.38,39 Opsonophagocyctic activity (OPA) against bacteria of
the vaccine serotypes was measured by a pneumococcal killing
assay with a cut-off titer of 8 as described previously.41,42 Differen-
tiated HL-60 cells were harvested at 37C in a 5% CO2 atmo-
sphere. Cells were resuspended in opsonophagocytosis buffer 10
minutes before use. For the functional assay, serially diluted sam-
ples were mixed with the appropriately diluted bacterial suspen-
sion and incubated before adding the complement source and
differentiated HL-60 cells. Viable colony counts were performed
after an 18 h incubation period. Test reagents, with the exception
of antibodies to pneumococci, were included in the complement
control wells. Sandoglobulin was used as reference preparation
with known OPA titer for each tested serotype. Opsonophago-
cytic titers were calculated as the reciprocal of the serum dilution
causing50% killing compared to the growth in the complement
control wells.41 Antibodies against non-typeable Haemophilus
influenzae (NTHi) protein D, Ply and PhtD were quantified using
GSK’s multiplex immunoassays with cut-offs of 112 LU/mL, 599
LU/mL and 391 LU/mL respectively. These cut-offs were based
on the lower limit of quantification, the global variability of the
assay at the highest dilution and the lower limit of linearity.43
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Statistical analyses
Safety analyses were performed on the total vaccinated cohort
(TVC) which comprised all children who were vaccinated.
Immunogenicity analyses were performed on the according-to-
protocol (ATP) cohort which was defined as vaccinated children
who met all eligibility criteria and complied with all study proce-
dures and for whom immunogenicity data were available. Geo-
metric mean antibody concentrations (GMC) and geometric
mean OPA titers (GMT) with their 95% confidence intervals
(CI) and percentages of children who attained the predefined
thresholds were determined.
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